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Abstract
Nisin is a bacteriocin widely utilized in more than 50 countries as a safe and natural antibacterial food preservative. It is the
most extensively studied bacteriocin, having undergone decades of bioengineering with a view to improving function and
physicochemical properties. The discovery of novel nisin variants with enhanced activity against clinical and foodborne
pathogens has recently been described. We screened a randomized bank of nisin A producers and identified a variant with a
serine to glycine change at position 29 (S29G), with enhanced efficacy against S. aureus SA113. Using a site-saturation
mutagenesis approach we generated three more derivatives (S29A, S29D and S29E) with enhanced activity against a range
of Gram positive drug resistant clinical, veterinary and food pathogens. In addition, a number of the nisin S29 derivatives
displayed superior antimicrobial activity to nisin A when assessed against a range of Gram negative food-associated
pathogens, including E. coli, Salmonella enterica serovar Typhimurium and Cronobacter sakazakii. This is the first report of
derivatives of nisin, or indeed any lantibiotic, with enhanced antimicrobial activity against both Gram positive and Gram
negative bacteria.
Citation: Field D, Begley M, O’Connor PM, Daly KM, Hugenholtz F, et al. (2012) Bioengineered Nisin A Derivatives with Enhanced Activity against Both Gram
Positive and Gram Negative Pathogens. PLoS ONE 7(10): e46884. doi:10.1371/journal.pone.0046884
Editor: Mark R. Liles, Auburn University, United States of America
Received July 3, 2012; Accepted September 7, 2012; Published October 8, 2012
Copyright:  2012 Field et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Irish Government under the National Development Plan, through Science Foundation Ireland Investigator awards (10/
IN.1/B3027) and (06/IN.1/B98) (http://www.sfi.ie). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: paul.cotter@teagasc.ie (PDC); c.hill@ucc.ie (CH)
Introduction
Nisin is the most important commercially exploited member of
the heterogeneous family of bacteriocins, antimicrobial peptides
produced by bacteria that can kill or inhibit the growth of other
bacteria [1]. It is the most highly characterized member of about
60 or so Class 1 bacteriocins, also termed lantibiotics. These are
characterized by the presence of post-translationally modified
unusual amino acids including lanthionine and/or methyllanthio-
nine. These unusual residues are generated by a series of enzyme-
mediated modifications that confer a distinct structure and
stability. Many lantibiotics, including nisin, lacticin 3147 and
mersacidin, are extremely potent and are active against a range of
Gram positive targets including antibiotic resistant pathogens [2–
6] as well as important food pathogen and spoilage organisms
[7,8]. Many lantibiotics are produced by lactic acid bacteria,
industrially important food microorganisms that are classified as
generally regarded as safe. Several have also been found to
function by targeting the essential precursor of the bacterial cell
wall, lipid II [9,10], which is also a target for at least four different
classes of antibiotic, including the glycopeptide vancomycin. A key
advantage of lantibiotics over classical antibiotics is that they are
gene-encoded and are thus much more amenable to bioengineer-
ing-based strategies with a view to further enhancing their
capabilities. Indeed, bioengineering of lantibiotics has been
underway for over two decades (for reviews see [11–14] and has
provided a considerable insight into the structure and function of
these peptides. It is only in recent years that researchers, armed
with a greater understanding of lantibiotic biology and the
application of bioengineering strategies on a larger-scale, have
achieved notable successes with regard to enhancing the antimi-
crobial activity of lantibiotics against pathogenic bacteria. Both
mersacidin and nukacin have been the subject of comprehensive
site-saturation mutagenesis approaches which have resulted in the
generation of several novel derivatives with enhanced activity
compared to the parent peptide [15,16]. In the case of mersacidin,
this included variants with enhanced activity against methicillin
resistant Staphylococcus aureus (MRSA), vancomycin resistant
enterococci (VRE) and S. pneumonia. Nisin itself has been subjected
to bioengineering for almost twenty years [17–26]. For a
comprehensive overview of the data generated by these studies
the reader is directed to a number of reviews on the topic ([12–
14,27]. Despite the large collection of derivatives which have been
generated, relatively few have been found to exhibit enhanced
activity against pathogenic microorganisms. An obvious exception
relates to derivatives generated by targeting a short 3 amino acid
stretch (Asn20-Met21-Lys22) in the centre of the peptide, known
as the ‘hinge-region’. Initial success was achieved through the
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generation of two mutants, N20K and M21K (Fig. 1), which
displayed enhanced activity against Gram negative bacteria
including Shigella, Pseudomonas and Salmonella spp. [28]. The
generation of nisin derivatives with enhanced activity against
Gram positive pathogens was achieved 4 years later using a non-
targeted approach [29]. In this instance, the use of a random
mutagenesis-based approach to create approximately 8000 nisin
derivatives led to the identification of one variant, K22T (Fig. 1),
that displayed enhanced activity against Streptococcus agalactiae, a
human and bovine pathogen. Prompted by the identification of yet
another ‘hinge’ derivative with enhanced activity, a more extensive
‘hinge-specific’ mutagenesis strategy was undertaken. This led to
the identification of further derivatives of note. Four of these were
selected for closer inspection [29], with M21V (Fig. 1) being
particularly notable by virtue of its enhanced antimicrobial activity
against a wide range of targets, including medically significant
pathogens such as heterogenous Vancomycin intermediate Staph-
ylococcus aureus (hVISA), VRE, MRSA, Clostridium difficile, S.
agalactiae and Listeria monocytogenes [29,30]. This enhanced activity
was also apparent in a food setting [30]. Studies with nisin K22T
(nisin T) revealed it to be more potent than nisin A against
veterinary isolates of S. aureus, S. agalactiae [30] and M. tuberculosis
[31] while N20P (nisin P) (Fig. 1) is noteworthy by virtue of the
target specific nature of its enhanced activity [29]. More recently,
a number of additional nisin ‘hinge’ derivatives have also been
identified which exhibit enhanced activity relative to nisin A in
complex matrices [32].
Prompted by the success of the aforementioned random
mutagenesis approach, we further screened the bank of randomly
generated nisin derivatives using additional target species not
included in previous studies (S. aureus SA113 and L. monocytogenes
LO28). One derivative (S29G) displayed enhanced activity against
S. aureus SA113. S29G was subjected to complete saturation
mutagenesis to investigate the impact of replacing serine with all
19 other standard amino acids on the bioactivity of nisin. The
results reveal the importance of position 29 with respect to the
activity of nisin and have for the first time led to the identification
of derivatives with enhanced activity against both Gram positive
and Gram negative pathogens.
Materials and Methods
Bacterial Strains and Growth Conditions
The bacterial strains used in this study are listed in Table 1.
L. lactis strains were grown in M17 broth supplemented with 0.5%
glucose (GM17) or GM17 agar at 30uC. S. aureus strains were
grown in Mueller-Hinton (MH) broth (Oxoid) or MH agar at
37uC, streptococci and Bacillus strains were grown in Tryptic soy
broth (TSB) or TSB agar at 37uC, Listeria strains were grown in
Brain Heart Infusion (BHI) or BHI agar at 37uC. C. sakazakii,
E. coli and Salmonella strains were grown in Luria-Bertani broth
with vigorous shaking or agar at 37uC unless otherwise stated.
Antibiotics were used where indicated at the following concentra-
tions: Chloramphenicol at 10 and 20 mg ml21, respectively for
L. lactis and E. coli. Tetracycline was used at 10 mg ml21for L. lactis
and E. coli.
Random Mutagenesis
DNA obtained from L. lactis NZ9700 [33] was used as template
for the amplification of a 372 bp fragment encompassing the nisA
gene with KOD polymerase (Novagen) using the primers oDF101
and oDF102 (Table 2). PCR amplicons were purified using the
QIAquick PCR purification kit (QIAGEN Inc.), digested with
BglII and XbaI (Roche) and cloned into similarly digested and
Shrimp Alkaline Phosphatase (SAP; Roche) treated pPTPL.
Following introduction into E. coli MC1000, plasmid was isolated
from one clone and was sequenced (MWG Biotech, Germany)
using the primer TETK P1 to ensure its integrity. The
introduction of this plasmid, pDF03, into competent L. lactis
NZ9800 successfully reinstated nisin activity. To provide sufficient
quantities of template DNA for error-prone PCR (ep-PCR), nisA
was reamplified using pDF03 as template with KOD polymerase
Figure 1. Structures of natural nisin and enhanced bioengineeredvariants. Six natural variants are known, nisin A, Z, F, Q, U and U2. Black
circles indicate amino acid differences between the natural nisin variants. Broken arrows denote enhanced activity of bioengineered nisin A or Z as a
result of single amino acid alterations [28,29,52], and/or combination of amino acid substitutions (joined circles) [22]. Residues are represented in the
single letter code. Post translational modifications are indicated as follows, Dha: dehydroalanine, Dhb: dehydrobutyrine, Abu: 2-aminobutyric acid,
Ala-S-Ala: lanthionine, Abu-S-Ala: 3-methyllanthionine. Adapted from [14].
doi:10.1371/journal.pone.0046884.g001
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using the primers oDF101 and oDF103, digested with Xba1 and
EcoR1 and cloned into similarly digested pUC19. Following
introduction into E. coli Top 10 (Invitrogen), plasmid was isolated
from one clone and was sequenced (MWG Biotech, Germany)
using the primers M13FOR and M13REV to ensure its integrity.
This plasmid, pDF04 was isolated from 100 ml overnight culture
using the Maxi-prep plasmid kit (QIAGEN Inc.) to a concentra-
tion of approx 1,100 ng/ml. pDF04 was used as template for the
Genemorph II random mutagenesis kit (Stratagene) according to
manufacturer’s guidelines. To introduce an average of one base
change in the 372 bp cloned fragment, amplification was
performed in a 50 ml reaction containing approximately 500 ng
of target DNA (pDF04), 2.5 units Mutazyme DNA polymerase,
1 mM dNTPs and 200 ng each of primers oDF101 and oDF102.
The reaction was preheated at 96uC for 1 min, and then
incubated for 22 cycles at 96uC for 1 min, 52uC for 1 min and
72uC for 1 min, and then finished by incubating at 72uC for
10 min. Amplified products were purified by gel extraction using
the Qiaquick gel extraction kit (QIAGEN Inc), and reamplified
with KOD polymerase before being digested with BglII and XbaI
(Roche), ligated with similarly digested and SAP treated pPTPL
and introduced into E. coli MC1000. To determine if the correct
rate of mutation had been achieved recombinant plasmid DNA
was isolated from selected clones using the QIAprep Spin
miniprep kit (QIAGEN Inc) and sequenced (MWG Biotech).
Transformants were pooled and stored in 80% glycerol at 220uC.
Plasmid DNA isolated from the mutant bank was used to
transform L. lactis NZ9800. Transformants (approx. 8000) were
isolated from Q trays using the Genetix QPIX II-XT colony-
picking robot and inoculated into 96 well plates containing GM17
freezing buffer, incubated overnight and subsequently stored at
220uC.
Saturation Mutagenesis
To generate a template for mutagenesis, the 372 base pair
fragment encompassing the nisA gene was amplified with KOD
polymerase using the primers oDF102 and oDF103, was digested
and subsequently cloned into pCI372. Following introduction into
E. coli Top 10 cells, plasmid was isolated from one clone and was
sequenced (MWG Biotech, Germany) using the primer
pCI372REV to ensure its integrity. Saturation mutagenesis of
the serine codon at position 29 of nisA was carried out with pDF05
(pCI372-nisA) as template and using oligonucleotides NisS29deg-
FOR and NisS29degREV (Table 2) containing an NNK codon in
place of each native codon. PCR amplification was performed in a
50 ml reaction containing approximately 0.5 ng of target DNA
(pDF05), 1 unit Phusion High-Fidelity DNA polymerase (Finn-
zymes, Finland), 1 mM dNTPs and 500 ng each of the
appropriate forward and reverse oligonucleotide. The reaction
was preheated at 98uC for 2 mins, and then incubated for 29
cycles at 98uC for 30 secs, 55uC for 15 secs and 72uC for 3 mins
Table 1. Strains used in this study.
Strains Relevant characteristics Reference
L. lactis NZ9700 Wild type Nisin producer [53,54]
L. lactis NZ9800 L. lactis NZ9700DnisA [53,54]
L. lactis NZ9800pDF05 L. lactis NZ9800 harboring pCI372 with nisA under its own promoter [29]
L. lactis NZ9800pDF03 L. lactis NZ9800 harboring pPTPL with nisA under its own promoter [29]
E. coli Top10 Intermediate cloning host Invitrogen
E. coli MC1000 E. coli host for pPTPL [55]
Indicator organisms
Strep. agalactiae ATCC13813 Nisin sensitive indicator ATCC
Strep. mitis UCC5001 Nisin sensitive indicator UCC Culture Collection
S. aureus RF122 Nisin sensitive indicator DPC Collection
S. aureus Sa113 Nisin sensitive indicator UCC Culture Collection
ST 528a Nisin sensitive indicator BSAC
ST 530a Nisin sensitive indicator BSAC
hVISA 32679b Nisin sensitive indicator BSAC
L. monocytogenes 10403S Nisin sensitive indicator UCC Culture Collection
L. monocytogenes LO28 Nisin sensitive indicator UCC Culture Collection
B. cereus DPC 6088 Nisin sensitive indicator DPC Collection
B. cereus DPC 6089 Nisin sensitive indicator DPC Collection
L. lactis spp cremoris HP Nisin sensitive indicator UCC Culture Collection
L. lactis MG1363 Nisin sensitive indicator UCC Culture Collection
E. durans 5133 Nisin sensitive indicator DPC Collection
E. coli 0157-H7 Nisin sensitive indicator UCC Culture Collection
C. sakazakii DPC 6440 Nisin sensitive indicator DPC Collection
Salmonella enterica serovar Typhimurium UK1 Nisin sensitive indicator UCC Culture Collection
DPC - Dairy Products Research Centre, BSAC – British Society for Antimicrobial Chemotherapy, ATCC – American Type Culture Collection,
aMethicillin resistant S. aureus.
bheterogenous Vancomycin-intermediate S. aureus.
doi:10.1371/journal.pone.0046884.t001
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30 secs, and then finished by incubating at 72uC for 3 mins
30 secs. Amplified products were treated with Dpn1 (Stratagene)
for 60 mins at 37uC to digest template DNA and purified using the
QIAquick PCR purification kit. Following transformation of E. coli
Top 10 cells plasmid DNA was isolated and sequenced using the
primers pCI372FOR and pCI372REV (Table 2) to verify that
mutagenesis had taken place. The purified products were
subsequently introduced by electroporation into the strain
NZ9800 which has all the genes necessary for nisin production.
Approximately 180 transformants were chosen at random and
inoculated into 96 well plates containing GM17 chloramphenicol,
incubated overnight and stored at 220uC after addition of 80%
glycerol.
Site-directed Mutagenesis to Obtain S29Q
To obtain the last remaining unidentified variant S29Q, site-
directed mutagenesis was undertaken using the oligonucleotides
nisS29QFor and nisS29QRev (Table 2). Approximately 0.5 ng of
the plasmid pDF05 (pCI372-nisA) was used as template for the
PCR reaction which was performed in a 50 ml reaction containing
1 unit Phusion High-Fidelity DNA polymerase (Finnzymes,
Finland), 1 mM dNTPs and 500 ng each of the appropriate
forward and reverse oligonucleotide. The reaction was preheated
at 98uC for 2 mins, and then incubated for 29 cycles at 98uC for
30 secs, 55uC for 15 secs and 72uC for 3 mins 30 secs, and then
concluded by incubating at 72uC for 3 mins 30 secs. Amplified
products were treated with Dpn1 (Stratagene) for 60 mins at 37uC
to digest template DNA and purified using the QIAquick PCR
purification kit. The purified products were subsequently intro-
duced by electroporation into the strain NZ9800. Transformants
were subjected to mass spectrometry to identify peptides with a
mass corresponding to 3394 amu indicative of the desired S29Q
mutation.
Nisin Purification
L. lactis NZ9700 (nisin A producer) or the mutant nisin strain of
interest was subcultured twice in GM17 broth at 1% at 30uC
before use. Two litres of modified TY broth were inoculated with
the culture at 0.5% and incubated at 30uC overnight. The culture
was centrifuged at 7,000 rpm for 15 minutes. The cell pellet was
resuspended in 300 mls of 70% 2-propanol 0.1% trifluoroacetic
acid (TFA) and stirred at room temperature for approximately 3h.
The cell debris was removed by centrifugation at 7,000 rpm for 15
minutes and the supernatant retained. The 2-propanol was
evaporated using a rotary evaporator (Buchi) and the sample pH
adjusted to 4 before applying to a 10g (60 ml) Varian C-18 Bond
Elut Column (Varian, Harbor City, CA) pre-equilibrated with
methanol and water. The columns were washed with 100 mls of
20% ethanol and the inhibitory activity was eluted in 100 mls of
70% 2-propanol 0.1% TFA. 15 ml aliquots were concentrated to
2 ml through the removal of 2-propanol by rotary evaporation.
1.5 ml aliquots were applied to a Phenomenex (Phenomenex,
Cheshire, UK) C12 reverse phase (RP)-HPLC column (Jupiter 4u
proteo 90 A˚, 250610.0 mm, 4 mm) previously equilibrated with
25% 2-propanol, 0.1% TFA. The column was subsequently
developed in a gradient of 30% 2-propanol containing 0.1% TFA
to 60% 2-propanol containing 0.1% TFA from 10 to 45 minutes at
a flow rate of 1.2 ml min21.
Mass Spectrometry
For Colony Mass Spectrometry (CMS) bacterial colonies were
collected with sterile plastic loops and mixed with 50 ml of 70%
isopropanol adjusted to pH 2 with HCl. The suspension was
vortexed, the cells centrifuged in a benchtop centrifuge at 14,000
r.p.m. for 2 mins, and the supernatant was removed for analysis.
Mass Spectrometry in all cases was performed with an Axima
CFR plus MALDI TOF mass spectrometer (Shimadzu Biotech,
Manchester, UK). A 0.5 ml aliquot of matrix solution (alpha-
cyano-4-hydroxy cinnamic acid (CHCA), 10 mg ml21 in 50%
acetonitrile-0.1% (v/v) trifluoroacetic acid) was placed onto the
target and left for 1–2 mins before being removed. The residual
solution was then air-dried and the sample solution (resuspended
lyophilised powder or CMS supernatant) was positioned onto the
precoated sample spot. Matrix solution (0.5 ml) was added to the
sample and allowed to air-dry. The sample was subsequently
analysed in positive-ion reflectron mode.
Bioassays for Antimicrobial Activity
Deferred antagonism assays were performed by replicating
strains on GM17 agar plates and allowing them to grow overnight
before overlaying with either GM17/BHI/TSB-YE/MH agar
(0.75% w/v agar) seeded with the appropriate indicator strain. For
higher throughput screening of the S29X bank, deferred
antagonism assays were performed by replicating strains using a
96 pin replicator (Boekel) or spotting 5 ml of a fresh overnight
culture on GM17 agar plates and allowing them to grow
overnight. Following overnight growth the strains were subjected
to UV radiation for 30 minutes prior to overlaying with either
GM17/BHI/TS/MH agar (0.75% w/v agar) seeded with the
appropriate indicator.
Agarose-based deferred antagonism assays were carried out as
follows: GM17/LB (0.03%) underlay was prepared with 10 mM
sodium phosphate buffer (SPB) at pH 7.4 to which was added
agarose (1% w/v agarose), autoclaved and cooled to 50uC.
Bacteria grown to mid-logarithmic phase were harvested by
centrifugation and washed with 10 mM SPB at pH 7.4. Bacteria
were then added to 15 mls cooled underlay medium to reach a
concentration of 26107 colony-forming units (CFU)/mL. The
inoculated medium was rapidly transferred into sterile Petri plates,
allowed to solidify and dried. Wells (4.6 mm in diameter) were
then made in the seeded plates. 10 ml volumes of cell-free
supernatant from overnight nisin derivative producing cultures
Table 2. Oligonucleotides used in this study.
Primer name Sequence
oDF101 59TCAGATCTTAGTCTTATAACTATACTG 39
oDF102 59 TGTCTAGATTATTTGCTTACGTGAATA 39
oDF103 59 CGGAATTCTAGTCTTATAACTATAGTGA 39
oDF105 59 AACTGCAGTATAGTTGACGAATA 39
oDF106 59 TAGAATTCAACAGACCAGCATTA 39
M13FOR 59 GTAAAACGACGGCCAGTG 39
M13REV 59 GGAAACAGCTATGACCATG 39
NisS29degFOR 59 Pho-TGTCATTGTNNKATTCACGTAAGCAAATAA 39
NisS29degREV 59 TACGTGAATMNNACAATGACAAGTTGCTGTTTTCATGTT 39
NisS29QFOR 59 Pho- TGT CAT TGT CAG ATT CAC GTA AGC AAA TAA
NisS29QREV 59 TAC GTG AAT CTG ACA ATG ACA AGT TGC TGT TTT CAT GTT
pCI372FOR 59- CGGGAAGCTAGAGTAAGTAG -39
pCI372REV 59- ACCTCTCGGTTATGAGTTAG -39
Underlined sequences represent restriction sites. Boldface represents
randomised nucleotides (N =A+C+G+T, K =G+T, M=A+C). Italics represent
altered codons.
doi:10.1371/journal.pone.0046884.t002
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or resuspended purified peptides were then added to the wells and
the plates incubated at 30uC (L. lactis) or 37uC (Gram positive
strains) or RT (Gram negative strains) for 3 hours. Polymyxin B
(Sigma Aldrich) was used at a concentration of 20 mg/ml. The
plates were then overlaid with 15 mls of autoclaved double
strength GM17 (L. lactis) or LB (Gram negatives) agarose (1% w/v
agarose) overlay medium precooled to 50uC. The plates were then
incubated overnight at the relevant temperature.
Minimum Inhibitory Concentration Assays
Minimum inhibitory concentration determinations for Gram
positive organisms were carried out in triplicate in microtitre plates
(Sarstedt). 96 well microtitre plates were pre-treated with bovine
serum albumin (BSA) prior to addition of the peptides. Briefly, to
each well of the microtitre plate 200 mL of phosphate buffered
saline (PBS) containing 1% (w/v) bovine serum albumin (PBS/
BSA) was added and incubated at 37uC for 30 min. The wells
were washed with 200 mL PBS and allowed to dry. Target strains
were grown overnight in the appropriate conditions and medium,
subcultured into fresh broth and allowed to grow to an OD600 of
,0.5, diluted to a final concentration of 105 cfu ml21 in a volume
of 0.2 ml. Wild type nisin and nisin mutant peptides were adjusted
to a 10 mM (S. mitis, B. cereus), 7.5 mM (L. monocytogenes), 5 mM
(hVISA) 2.5 mM (MRSA, E. durans), or 500 nM (L. lactis strains)
starting concentration and 2-fold serial dilutions of each peptide
were added to the target strain. After incubation for 16 h at 37uC
the MIC was read as the lowest peptide concentration causing
inhibition of visible growth.
Minimum inhibitory concentration determinations for Gram
negative strains were carried out in triplicate in 96 well microtitre
plates. Briefly, bacteria (E. coli, C. sakazakii and Salmonella) grown to
mid-logarithmic phase were harvested by centrifugation, washed
with 10 mM SPB at pH 7.4, and diluted to 26105 colony-forming
units (CFU)/mL in SPB. Nisin and nisin derivative peptides were
resuspended in sterile HPLC water and 50 mL aliquots were added
to wells containing 50 mL of 26105 CFU of bacteria. Plates were
incubated at RT for two hours with agitation. Double strength
Luria–Bertani (LB) broth (100 mL) was added and the plates were
incubated at RT overnight, the MIC was taken as the lowest
concentration at which growth was inhibited.
Results
Screening a Bank of Random Nisin Peptides
Although random mutagenesis approaches have rarely been
applied to lantibiotics, the recent randomization of the nisin A
structural gene led to the identification of a beneficial change with
respect to anti-Gram positive activity [29]. Follow-up site-directed
and site-saturation mutagenesis within the same region, corre-
sponding to the ‘hinge’ of the peptide, identified three further
beneficial mutations with respect to antimicrobial activity [29].
Given that only two indicators (L. lactis HP and S. agalactiae
ATCC13813) were employed during the original screen of the
random bank of .8,000 nisin-producing derivatives, a decision
was made to re-screen this bank using S. aureus SA113 and
L. monocytogenes LO28 as targets. The strategy proved successful in
that it revealed one isolate that displayed superior bioactivity
against S. aureus SA113 (Fig. 2), but which exhibited an activity
comparable to that of nisin A against L. monocytogenes LO28 (data
not shown). Bioactivity refers to the zone of inhibition surrounding
a producer colony, or the zone created in a deferred antagonism
assay. This could be a result of increased specific activity,
enhanced solubility or even enhanced production, but serves as
a useful first step in identifying beneficial changes. The enhanced
isolate was selected for closer inspection. A peptide mass of
3322.97 Da (Fig. 2) determined by colony mass spectrometry
(CMS) suggested a S29G alteration had occurred in the mature
peptide. This was in agreement with DNA sequence analysis
which confirmed that the serine at position 29 was altered. This is
an unusual residue in that it is the only potentially modifiable
residue (serine, threonine or cysteine) in nisin A that remains
unmodified. It is also the first residue of a 6 amino acid stretch
directly following rings D and E located in the C-terminus of nisin
(Fig. 1), which is thought to insert into target membranes to form
pores [34].
Creation and Analysis of a Bank of Nisin A Serine29
Derivatives
Serine 29 has previously been shown to be an important residue
with respect to activity (truncated versions of nisin, nisin 1–29 and
nisin 1–28, display 16 and 100 fold reduced activity, respectively
[35,36]. We decided that further targeting of this position was
warranted. A saturation mutagenesis approach was undertaken,
similar to the strategy carried out previously [29]. This involves
using oligonucleotides to replace the specific codon (in this case the
AGT coding for serine 29) with an NNK triplet, potentially
encoding all 20 standard amino acids. Complete plasmid
amplification of pDF05 (nisA cloned into a shuttle vector,
pCI372) was carried out and the products were transformed into
an E. coli Top10 host. Following plasmid extraction, the pooled
bank of pDF05 derivatives was introduced into L. lactis NZ9800 to
allow expression of the mutant nisin A peptides for further
analysis. The bioactivity of approximately 200 L. lactis NZ9800
pDF05 derivatives was assessed using deferred antagonism assays
against a range of target indicator organisms including S. aureus
RF122, L. monocytogenes LO28, S. agalactiae ATCC13813 and
L. lactis ssp cremoris HP. In addition, the same derivatives were
analyzed by Mass Spectrometry to identify the extent and nature
of the amino acid substitutions which had occurred. The strategy
proved highly successful in that 19 of the potential 20 alterations
were detected (Table 3). To complete the collection, site-directed
mutagenesis was employed to create the final derivative, S29Q.
Screening of this collection of Ser29 derivatives revealed that a
number of derivatives, or the supernatants they produced,
exhibited superior activity to nisin A producers in agar-based
deferred antagonism assays and agarose-based antimicrobial
assays against L. lactis HP (Fig. 3), S. aureus RF122 and S. agalactiae
ATCC13813 (data not shown). The bioactivity of the S29G
variant generated was enhanced as expected, while three
additional variants also exhibited enhanced activity against at
least one target. These derivatives produced peptides with S29A,
S29D and S29E changes (Fig. 3A), as confirmed by mass
spectrometry and DNA sequencing.
These assays also provided valuable information regarding the
consequences of incorporating other residues at this location.
These consequences can be grouped according to the nature of the
newly incorporated residue and, in this instance, were compared
in terms of their relative impact on bioactivity against L. lactis HP
(Table 4). Nisin A is naturally devoid of aromatic residues, and all
bioengineered derivatives in which aromatic residues have been
incorporated have displayed reduced antimicrobial activity (I1W,
M17W, N20F, N20Y, N20W, M21F, M21Y, M21W, K22F,
K22W, V32W, I30W, and N20F/M21L/K22Q [28,37,38]. This
pattern is again apparent from our studies in that S29F, S29Y and
S29W changes were all found to impact negatively on bioactivity
(Table 4).
Nisin A is cationic due to the presence of 5 positively charged
residues (Lys12, Lys22, Lys34, His27, His31) and the absence of
Nisin S29 Derivatives
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negatively charged equivalents. To date, the effect of manipulating
the charge of nisin has had variable outcomes. This may be a
consequence of the location at which the charge residues are
incorporated. For instance, the introduction of negatively charged
residues into the hinge region has had a detrimental impact
(N20D, N20E, M21E, K22D and K22E; [28,29] whereas the
introduction of positively charged residues has had a more
beneficial impact on anti-Gram-negative activity (N20K and
M21K; [28]. Given the importance of positive charge for the
initial attraction of many cationic peptides to the cell envelope, it
was surprising to find that the introduction of negatively charged
residues (S29D, S29E) resulted in the corresponding peptides
exhibiting superior bioactivity. S29D and S29E derivatives also
displayed higher bioactivity than that of wild type nisin A producer
against L. lactis HP (Table 4). In contrast, the replacement of serine
29 with positively charged residues had a negative impact in that
the variants with S29R, S29H and S29K changes demonstrated
reduced bioactivity.
Replacement of serine with threonine also produced a peptide
with a moderate reduction in activity. The mass of this peptide was
consistent with the presence of threonine in its unmodified form
(3366.75 Da).
In the past, the introduction of hydrophobic residues have had
varied impacts on the bioactivity of nisin. In the case of the hinge-
region, the introduction of isoleucine, leucine, and methionine (in
the latter case at positions 20 or 22) resulted in decreased
bioactivity in the majority of cases. In contrast, the introduction of
a proline at Asn20 (N20P) or a valine at Met21 (M21V) resulted in
peptides with enhanced activity [29,30]. In the present study, the
incorporation of isoleucine, leucine, proline and methionine at
position 29 resulted in modest reductions in bioactivity against
L. lactis HP (Table 4).
The impact on bioactivity as a result of the incorporation of
small and nucleophilic residues has generally been favorable,
particularly with respect to the hinge region [29]. As noted above,
the introduction of a glycine at position 29 (S29G) increases the
bioactivity of the corresponding strain against S. aureus RF122.
However, the bioactivity of this strain against L. lactis HP is
comparable to that of nisin A (Table 4) while the incorporation of
alanine (S29A) has a more beneficial impact (Table 4). Finally, the
Figure 2. Bioactivity and mass spectrometry analysis of nisin A and nisin A S29G. Growth inhibition of (A) S. aureus SA113 by the nisin A
producing strains NZ9800pPTPL-nisA and NZ9800pPTPL-nisA S29G (B) Colony Mass Spectrometry analysis of nisin A (3352.63 amu) and the nisin A
S29G (3322.97 amu) derivative.
doi:10.1371/journal.pone.0046884.g002
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derivatives S29N and S29Q exhibited 83% and 100% of wild type
activity, respectively.
As a consequence of the apparent improved bioactivity of the
producers of the nisin A S29G, S29A, S29D and S29E derivatives
against at least one target, these four derivatives were purified in
order to determine if enhanced bioactivity was attributable to
enhanced specific activity.
Specific Activities of Nisin A S29G, S29A S29D and S29E
against Gram Positive Microorganisms
Although agar-based assays are commonly used for antibiotic
MIC determinations in solid media, a number of drawbacks have
been identified that relate to altered diffusion rates. This is
especially true for molecules of a more hydrophobic or
amphiphillic nature, or ones which interact with the diffusion
medium, or suffer degradation or loss of substrate during diffusion
[39]. To ensure that the enhanced activity of the selected S29
derivatives was not as a consequence of altered diffusion rates, the
specific activity of the peptides was assessed against a wide range of
organisms using classical broth-based minimum inhibitory con-
centration (MIC) determination assays. Targets included the
antibiotic resistant S. aureus strains ST 528 (MRSA), ST 530
(MRSA), hVISA 32679, as well as S. aureus RF122, Streptococcus
mitis, L. lactis HP and MG1363, Bacillus cereus DPC 6088/6089,
Enterococcus durans and L. monocytogenes strains 10403S and LO28.
Using equimolar concentrations of purified peptides, the specific
activities of S29G, S29A, S29D and S29E were determined
(Table 5). For the purpose of comparison, a M21K derivative of
nisin A was also generated and purified. A M21K derivative of
nisin Z was previously found to possess enhanced activity against
some Gram negative targets. These investigations established that
the MIC of nisin A against MRSA strains ST 528 and ST 530 was
0.5 and 0.5 mg/L, respectively (Table 5), which was in close
agreement with previous results [3]. Both nisin S29G and S29A
were two-fold more active than nisin A against both of these
targets (0.26 mg/L in each case). One of the other serine 29
derivatives, S29D, displayed a similarly enhanced specific activity
against one of these strains, MRSA ST 528. Furthermore, the
S29G and S29A derivatives also exhibited improved specific
activity against hVISA 32679, with MIC values of 2 mg/L and
2 mg/L, respectively, compared to an MIC of 4 mg/L for nisin A
(Table 5). Against the MSSA (methicillin sensitive S. aureus) strain,
S. aureus RF122, both S29G and S29A also outperformed nisin A
Figure 3. Deferred antagonism assays of nisin A S29 derivatives against the nisin-sensitive indicator Lactococcus lactis HP. (A) spot on
lawn of producing strains on GM17 agar and overlaid with GM17 agar (0.75%) seeded with HP and (B) supernatants of producing strains in agarose-
based (1%) GM17. Single letters correspond to IUPAC abbreviation code, wt = Serine.
doi:10.1371/journal.pone.0046884.g003
Table 3. MALDI TOF mass spectrometry analysis of nisin S29
saturation derivatives corresponding to all 20 standard amino
acids.
Amino acid Molecular Mass
S29X Predicted Actual
Asparagine N 3379.66 3379.05
Glutamine Q 3393.69 3393.23
Cysteine C 3368.70 3368.73
Glycine G 3322.60 3322.97
Alanine A 3336.64 3336.67
Serine S 3352.06 3352.63
Threonine T 3366.66 3366.75
Valine V 3364.69 3364.81
Leucine L 3378.71 3379.33
Isoleucine I 3378.71 3378.60
Proline P 3362.67 3362.73
Methionine M 3396.74 3396.15
Phenylalanine F 3412.73 3412.94
Tyrosine Y 3428.73 3429.17
Tryptophan W 3451.76 3451.61
Aspartic acid D 3380.64 3381.32
Glutamic acid E 3394.67 3395.56
Arginine R 3421.74 3421.93
Histidine H 3402.69 3404.15
Lysine K 3393.72 3394.73
doi:10.1371/journal.pone.0046884.t003
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(MICs of 0.52, 0.52 and 1.04 mg/L, respectively). However, the
‘charge’ mutants S29D and S29E were less active than wild type
against this target (4.19, 2.0 and 1.04 mg/L, respectively). In
contrast, S29D and S29E were found to be particularly active
when L. lactis HP was used as the indicator organism. While the
MIC for nisin A was 0.2 mg/L and that of both S29G and S29A
was 0.1 mg/L, the MICs of S29D and S29E were a mere
0.05 mg/L. This pattern appeared to be strain variable in that
when another L. lactis MG1363 strain was employed both S29G
and S29D were twice as active (0.4 mg/) as nisin A whereas in this
instance nisin S29A was most potent (four fold more active than
nisin A (0.2 and 0.8 mg/L, respectively). In contrast, the specific
activity of nisin S29E was equal to that of nisin A against L. lactis
MG1363.
Two other foodborne associated strains were selected for MIC
analysis, including isolates of Bacillus cereus and Enterococcus durans.
B. cereus is ubiquitous in the environment but is often found in food
production locations due to its ability to form biofilms and highly
adhesive endospores, enabling it to survive food processing
treatments [40]. Enterococci are present in high numbers in food
of animal origin [41] and vegetables [42] and are recognized as a
frequent cause of nosocomial infections [43]. The efficacies of
S29G and S29E were two-fold better against B. cereus DPC 6088
and DPC 6089 (Table 5), while S29A was also twice as potent as
nisin A against B. cereus DPC 6089 but displayed four-fold
improvement against B. cereus DPC 6088. In contrast, S29G was
the only derivative to display two-fold improvement against
E. durans 5133, while S29A displayed a four-fold increase in
potency to nisin A (0.13 mg/L and 0.52 mg/L, respectively
(Table 5).
Interestingly, although the specific activity of S29G was
enhanced against almost all Gram positive targets tested, in two
instances its activity equaled nisin A (Table 5). More specifically,
the MIC values for both S29G and nisin A against L. monocytogenes
LO28 and S. mitis UCC5001 were 6.28 and 8.38 mg/L,
respectively. In contrast, nisin S29A exhibited enhanced specific
activity against all Gram positive targets tested with MICs for
L. monocytogenes LO28 and S. mitis UCC5001 being 3.14 and
4.19 mg/L, respectively.
It has previously been reported that the activity of nisin Z
M21K is not enhanced against Gram positive targets [28].
Similarly, a L. lactis producer of M21K was found to display
bioactivity comparable to that of a nisin A producing control when
tested against the Gram positive targets S. aureus DPC 5245,
MRSA ST528 and S. agalactiae ATCC13813 [29]. Here, MIC-
based assays with M21K revealed that its specific activity against
L. lactis HP, S. aureus RF122, S. mitis UCC5001 and E. durans is
equal to that of nisin A but is reduced relative to nisin A against
B. cereus DPC 6088 and DPC 6089.
Specific Activities of Nisin A S29G, S29A, S29D and S29E
against Gram Negative Organisms
Although nisin A has strong antibacterial activity against Gram
positive organisms, the outer membrane (OM) of the Gram
negative cell wall acts as a barrier for the cell, restricting the access
of the peptide to the cytoplasmic membrane [44]. However,
certain treatments which can disrupt the outer membrane of
Gram negative bacteria can render them susceptible to nisin. Such
treatments include chelating agents such as EDTA [45], sub-lethal
heat, osmotic shock and freezing [46]. Furthermore, as noted
above, a study involving mutagenesis of the hinge region of nisin Z
Table 4. Agarose assay results of S29 derivatives against Lactococcus lactis HP.
Nisin derivative (S29X) Zone Diameter (mm) % difference (P value)
Hydrophillic : Neutral Serine (wt) 15.260.2 100
Threonine (T) 12.160.9 79
Glutamine (Q) 15.3±0.1 100
Asparagine (N) 12.6±1.0 83
Tyrosine (Y) 10.660.6 70
Hydrophillic : Charged Aspartate (D) 2ve 20.3±0.8 133 (0.006)
Glutamate (E) 2ve 18.6±0.3 122 (0.0004)
Arginine (R) +ve 11.0±0.6 72
Histidine (H) +ve 10.9±0.3 72
Lysine (K) +ve 9.9±1.0 64
Hydrophobic : Alanine (A) 16.6±0.3 109 (0.004)
Valine (V) 11.660.4 76
Glycine (G) 15.460.5 101
Cysteine 10.5±1.0 69
Leucine (L) 12.760.7 84
Isoleucine (I) 9.961.0 65
Tryptophan (W) 12.161.2 79
Phenylalanine (F) 11.061.0 72
Methionine (M) 13.6±0.8 89
Proline (P) 13.7±1.0 89
Results are expressed as zone diameter in mm. Bold font denotes activity greater than wild type nisin A. Values in bold reached statistical significance compared to a
nisin control (Student’s t-test: P,0.05).
doi:10.1371/journal.pone.0046884.t004
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uncovered two mutants N20K and M21K with enhanced
antimicrobial activity against the Gram negative targets Shigella,
Pseudomonas and Salmonella [28]. To assess the nisin S29 derivatives
against a selection of Gram negative targets of particular
foodborne significance, a modified agarose-based assay was
utilized to assess the activity of purified nisin A and the nisin A
S29G, S29A, S29D and S29E variants against C. sakazakii DPC
6440, E. coli 0157-H7 and Salmonella enterica serovar Typhimurium
UK1. The nisin A M21K was also purified with a view to
determining if it, like nisin Z M21K, showed enhanced anti-Gram
negative activity. This analysis revealed that nisin A M21K
exhibited improved activity against C. sakazakii, E. coli and
Salmonella strains (Table 6). Corresponding studies revealed that
the nisin S29E derivative exhibited increased activity against the
E. coli and Salmonella strains only and that the nisin S29D was less
active than nisin A against E. coli and Salmonella but exhibited
activity comparable to that of nisin A against the C. sakazakii target
(Table 6). In contrast, S29G and S29A displayed enhanced activity
against all three Gram negative targets tested. Nisin A S29A
consistently exhibited greatest potency in this regard (Table 6).
To further confirm the specific activity of the peptides, and to
ensure that these results were not a result of improved solubility in
solid agar, broth-based MIC determination assays were also
carried out using purified peptides against the same Gram negative
targets. The results closely matched the patterns obtained using
the agarose-based diffusion assays. More specifically, nisin A
M21K exhibited a two-fold increase in specific activity compared
to nisin A against all the targets tested (Table 7). Nisin A S29E was
more active than nisin A against E. coli (25.14 mg/L and
50.28 mg/L respectively) and Salmonella (50.28 mg/L and
.100 mg/L respectively) but not C. sakazakii, while nisin A
S29D was more active than nisin A against C. sakazakii only
(6.28 mg/L and 12.57 mg/L, respectively; Table 7). However,
both S29G and S29A were two fold more potent against all three
targets. These results establish that S29G and S29A variants differ
from all nisin derivatives generated to date in that they exhibit
enhanced activity against both Gram positive and Gram negative
targets. It was also notable that S29A was the only derivative
superior to nisin A against all strains utilized in this study.
Finally, while MIC analyses can demonstrate the increased
specific activity of a bioengineered peptide, their end point nature
does not provide information regarding the relative bactericidal
activity of peptides. To address this, the ability of S29G and S29A
to kill Gram negative targets was tested and compared with that of
nisin A.
Table 5. Minimum inhibitory concentration results of nisin derivatives against representative Gram positive strains.
STRAIN NisinA mg/L (mM) S29G mg/L (mM) S29A mg/L (mM) S29D mg/L (mM) S29E mg/L (mM) M21K mg/L (mM)
ST 528a 0.52 (0.156) 0.26 (0.078) 0.26 (0.078) 0.26 (0.078) 0.52 (0.15) nd
ST 530 a 0.52 (0.156) 0.26 (0.078) 0.26 (0.078) 0.52 (0.156) 0.52(0.15) nd
hVISA 32679 b 4.19(1.25) 2 (0.625) 2 (0.625) 4.19(1.25) 4.19(1.25) nd
L.mono10403S 12.57 (3.75) 6.28 (1.875) 6.28 (1.875) 12.57 (3.75) 12.57 (3.75) nd
L.mono LO28 6.28 (1.875) 6.28 (1.875) 3.14 (0.937) 12.57 (3.75) 6.28 (1.875) nd
L. lactis MG1363 0.8 (0.250) 0.4 (0.125) 0.2 (0.062) 0.4 (0.125) 0.8 (0.250) nd
L. lactis HP 0.2 (0.062) 0.1 (0.031) 0.1 (0.031) 0.05 (0.015) 0.05(0.015) 0.2 (0.062)
S. aureus RF122 1.04 (0.312) 0.52 (0.156) 0.52 (0.156) 4.19(1.25) 2 (0.625) 1.04 (0.312)
S. mitis UCC5000 8.38 (2.5) 8.38 (2.5) 4.19 (0.125) 16.76 (5.0) 4.19 (0.125) 8.38 (2.5)
B.cereus DPC 6088 8.38 (2.5) 4.19(1.25) 2 (0.612) 16.76 (5.0) 4.19(1.25) 16.76 (5.0)
B. cereus DPC 6089 8.38 (2.5) 4.19(1.25) 4.19(1.25) 8.38 (2.5) 4.19(1.25) 16.76 (5.0)
E. durans 5133 0.52 (0.156) 0.26 (0.078) 0.13 (0.039) 0.52 (0.156) 0.52 (0.156) 0.52 (0.156)
aMethicillin resistant S. aureus.
bheterogenous Vancomycin-intermediate S. aureus. nd-not determined.
Minimum inhibitory concentration results of purified nisin wild type peptide and the S29 derivatives S29G, S29A, S29D, S29E and the hinge derivative M21K against a
range of Gram positive indicators. Results are expressed as the mean of triplicate assays.
doi:10.1371/journal.pone.0046884.t005
Table 6. Results of agarose gel diffusion assays against representative Gram negative strains.
STRAIN NisinA mm
S29G mm
(% wt/Pvalue)
S29A mm
(% wt/P value)
S29D mm
(% wt/P value)
S29E mm
(% wt/P value)
M21K mm
(% wt/P value)
C. sakazakii DPC 6440 9.7760.17 10.7960.16
(110/0.002)
11.6560.12
(119/0.0002)
10.1060.19 (103) 7.9860.29 (81) 10.51±0.10
(108/0.005)
E. coli 0157-H7 9.8160.04 11.1060.05
(113/6E-06)
11.5060.05
(117/3E-06)
8.2760.08 (84) 10.5460.19
(107/5E-05)
10.80±0.01
(110/0.01)
Salmonella enterica serovar
Typhimurium UK1
9.8860.11 10.94±0.24
(111/0.008)
11.29±0.23
(114/0.003)
8.2260.16 (83) 10.77±0.07
(109/0.007)
10.75±0.12
(109/0.008)
Results from agarose gel diffusion assays of nisin and S29 variants using purified peptide (60 mM) against the Gram negative strains C. sakazakii DPC 6440, E. coli 0157-
H7 and Salmonella enterica serovar Typhimurium UK1. Values are the mean of triplicate agarose gel diffusion assays. All values in bold reached statistical significance
compared to the nisin control (Student’s t-test: P,0.05).
doi:10.1371/journal.pone.0046884.t006
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Using purified peptide in each case, 10 mM sodium phosphate
buffer washed C. sakazakii, E. coli and Salmonella strains were diluted
to a final concentration of 26105 cfu ml21 and were exposed to
nisin A, S29G and S29A at a concentration of 33 mg/L.
Following incubation at 37uC for 1 hour, bacterial growth was
monitored through plate counts. In all instances the novel
derivatives showed greater activity than wildtype nisin A (Fig. 4).
Assays with the polymyxin B nonapeptide (PMBN) were carried
out in order to gain an insight into the basis for the enhanced
activity of these derivatives against Gram negative targets.
Polymyxin B (PMB) is a cyclic lipodecapaptide produced by
bacteria of the genus Paenibacillus that acts primarily on the Gram
negative cell wall [47], leading to rapid permeability changes in
the cytoplasmic membrane and ultimately cell death. Polymyxin B
nonapeptide (PMBN) lacks the fatty acid tail of PMB and,
although it exhibits poor antimicrobial activity, it retains the ability
to effect significant permeabilization of the OM, thus rendering
Gram-negative bacteria susceptible to various hydrophobic
antibiotics [48]. Notably, nisin A and polymyxin B have been
shown to be more effective against Gram negative bacteria when
used in combination than when either is used alone [49]. We
sought to determine if the nisin derivatives S29G and S29A were
also more potent than nisin A against Gram negative bacteria in
which the OM no longer functions as an impenetrable barrier. To
that end, C. sakazakii DPC 6440 cells were treated with purified
nisin A, S29G and S29A peptides alone (30 mM) or in
combination with PMBN at a concentration of 20 mg/ml and
determined the antimicrobial activity by agarose gel diffusion assay
(Fig. 5). As was previously observed, the S29G and S29A
derivatives exhibited enhanced potency compared to nisin A
when used alone (48.260.7 [P = 0.01], 49.061.24 [P = 0.009] and
40.062.3 respectively) (Fig. 5). When used in combination with
PMBN, a substantial synergistic effect was clearly evident (Fig. 5)
but in this instance no significant difference in efficacy was
observed between nisin A or either of the derivatives S29A or
S29G. Thus the enhanced activity of S29A and S29G over nisin A
is only evident in situations where the OM is intact. These results
suggest that the enhanced activity of the nisin derivative peptides
against Gram negatives is as a result of an increased ability to
traverse the OM relative to the nisin A peptide.
Discussion
The ribosomally synthesised nature of lantibiotics and the
consequent ability to conduct comprehensive bioengineering
strategies provides tremendous potential for the development of
more effective antimicrobials for food and medical applications. In
this study, the screening of a randomly mutated bank of nisin
derivatives produced a variant with superior activity against the
strain S. aureus SA113. The increased efficacy resulted from a
single mutation located at serine 29, within the C-terminal of nisin.
The importance of Serine 29 for activity has previously been noted
when Chan et al reported that the removal of five or nine residues
Table 7. Minimum inhibitory concentrations of nisin derivatives against representative Gram negative strains.
STRAIN NisinA mg/L (mM) S29G mg/L (mM) S29A mg/L (mM) S29D mg/L (mM) S29E mg/L (mM) M21K mg/L (mM)
C. sakazakii DPC 6440 12.57(3.75) 6.28(1.875) 6.28(1.875) 6.28(1.875) 12.57(3.75) 6.28(1.875)
E. coli 0157-H7 50.28 (15) 25.14(7.5) 25.14(7.5) .100(.30) 25.14(7.5) 25.14(7.5)
Salmonella enterica serovar
Typhimurium UK1
.100(.30) 50.28 (15) 50.28 (15) .100(.30) 50.28 (15) 50.28 (15)
Minimum inhibitory concentration assays of purified nisin wild type and the derivatives S29G, S29A, S29D, S29E and the hinge variant M21K against the Gram negative
strains C. sakazakii DPC 6440, E. coli 0157-H7 and Salmonella enterica serovar Typhimurium UK1. Results are expressed as the mean of triplicate assays.
doi:10.1371/journal.pone.0046884.t007
Figure 4. Kill curve analysis of strains C. sakazakii DPC 6440,
S. typhimurium UK-1 and E. coli in 33mg/L respectively of nisin
A, S29A and S29G.
doi:10.1371/journal.pone.0046884.g004
Figure 5. Activity of purified peptides against C. sakazakii DPC
6440. Activity of purified peptides of nisin A, S29G and S29A (30 mM)
against C. sakazakii DPC 6440 as determined by agarose gel diffusion
assay using (A) peptide alone and (B) peptide in combination with
polymyxin B nonapeptide (PMBN) at a concentration of 20 mg/ml.
Results are expressed as total area of inhibitory zone expressed in mm2.
Values in bold reached statistical significance compared to the nisin
control (Student’s t-test: P,0.05).
doi:10.1371/journal.pone.0046884.g005
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from the C-terminal residues leads to a 16 fold or 110 fold
decrease in bactericidal potency compared with that of intact
nisin, respectively [35]. Additionally, Sun et al reported that nisin
1–28 also showed a 100 fold reduced inhibitory activity against
L. lactis MG1363 [36]. These data pointed to an important role for
Serine 29 in the activity of nisin and as a consequence, complete
saturation mutagenesis was undertaken to determine the impact
on nisin activity by substituting serine 29 with all the other
available 19 standard amino acids. The strategy proved successful
in that three more derivatives, S29A, S29D and S29E displayed
enhanced activity against a range of bacterial targets. It is
important to note that this improved activity was strain variable,
providing further evidence that nisin derivatives can be generated
with distinct target specificities. For example, studies with K22T
(nisin T) revealed it to be more potent than nisin A against
veterinary isolates of S. aureus and S. agalactiae [30] but not Listeria
monocytogenes, while N20P (nisin P) is also striking by virtue of the
target specific nature of its enhanced activity [29]. Similarly, S29D
and S29E displayed improved activity against a distinct number of
species, being particularly active against lactococci (Lactococcus lactis
HP and Lactococcus lactis MG1363). In contrast, S29A was more
potent than nisin A against all Gram positive and Gram negative
bacterial targets.
While nisin was first approved for use in 1969, its use is likely to
increase in the coming years due to the increased customer
demand for minimally processed foods lacking artificial or
chemical preservatives. A major concern in food safety is the
transmission of pathogenic enterobacteriaceae (Salmonella spp,
E. coli 0157:H7, Shigella spp) due to their major roles in foodborne
illness [8]. While nisin is a potent anti-Gram positive inhibitor, its
activity against Gram negative bacteria is poor. However, nisin
can be used in combination with other synergistic preservation
methods (known as hurdle technology), such as organic acids, low
pH, high salt concentrations, chelating agents, modified atmo-
sphere packaging, high hydrostatic pressure and thermal treat-
ments, to enhance anti-Gram negative activity [8]. The superior
activity of nisin A S29A compared to nisin A against Gram
negatives, together with its enhanced activity against all Gram
positive targets, suggests that S29A could find applications as a
food preservative.
Nisin is also used in the veterinary industry and has potential as
a clinical antimicrobial. Bovine mastitis is the cause of significant
economic loss to dairy operations. Annual losses are presently
estimated to be approximately $2 billion in the US alone [50].
Nisin A is already employed commercially as an anti-mastitis
product in the form of Wipe OutH, and an intramammary infusion
product Mast OutH, that are being developed as alternatives to
traditional antibiotics. Indeed, the Center for Veterinary Medicine
of the FDA has recently declared favourably on the application of
nisin for the intramammary treatment for subclinical mastitis.
More importantly, cattle would not be subject to a zero milk
discard and a zero meat withhold as a consequence of treatment.
Thus the existence of bioengineered nisin derivatives that
consistently exhibit enhanced activity against mastitis associated
pathogens such as the S. agalactiae and S. aureus RF122 strains
utilized in this study is noteworthy. Furthermore, Escherichia coli
can cause inflammation of the mammary gland in dairy cows
around parturition and during early lactation with striking local
and sometimes severe systemic clinical symptoms [51]. The
bacterium invades the udder through the teat canal and may
cause several cases of death per year in the most severe cases. The
enhanced nature of S29A and S29G against Gram negative
species such as E. coli as well as the major mastitis-associated Gram
positive species, implies that these derivatives could also reduce the
potential for economic loss as a result of their increased potency
and broader target range. Indeed, the synergism of nisin A in
combination with the polymyxin B nonapeptide reported here
would suggest a potential use for this potent combination to
control bovine mastitis and, potentially, other veterinary and
clinical infections. However, further study is required to establish
the mechanistic basis for the enhanced activity of the S29G and
S29A derivatives relative to nisin A. In particular, studies will focus
on further investigating the importance of the OM with respect to
their superior activity against Gram negative bacteria, for which
nisin is usually considered ineffective.
In conclusion, it is apparent that altering residue 29 of nisin A
can result in the generation of variants with enhanced antimicro-
bial activity. In some instances this enhancement varies depending
on the target microorganism but in other cases, particularly nisin
A S29A and, to a lesser extent, S29G, this enhancement is
consistent across a wide range of targets. The fact that this
enhancement is apparent against Gram positive and Gram
negative targets is particularly novel. Further efforts will focus on
determining the mechanistic basis for these enhancements and an
assessment of how well these peptides perform in food and in vivo.
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